Iovance Biotherapeutics, Inc. Common Stock Study update
Review the key takeaways and the transcript of this earnings call.
Transcript
Preview the first fifteen paragraphs, organized by speaker.
Welcome to the Iovance Biotherapeutics conference call to review updated data from the IOV-LUN-202 trial in non-small cell lung cancer.
Hello? Excuse me. My name is Carmen.
I'll be your operator for today.
Can you hear us? Hello?
Yes, we can hear you.
Hello? Yes, we can hear you.
We are live. We were introducing the call, Fred.
There are Try the dial-in.
Can you hear us? Ladies and gentlemen, please stand by.
Can you hear us? Yes, we can hear you, sir.
Go ahead and go live.
We're ready to start. We were live, sir.
As we were welcoming everybody to the Iovance Biotherapeutics conference call to review the updated data from the IOV-LUN-202 trial in non-small cell lung cancer. My name is Carmen. I will be your operator for today, and at this time everybody is on a listen-only mode. Later, we will conduct a question and answer session. Please note that this conference call is being recorded. I will now turn the call over to Sara Pellegrino, Senior Vice President, Investor Relations and Corporate Communications at Iovance. Sara, you may begin. Thank you.
Welcome to Iovance Biotherapeutics conference call to review updated data from IOV-LUN-202 in non-small cell lung cancer. Welcome to the webcast to review updated registrational trial data in previously treated non-squamous, non-small cell lung cancer and our biomarker-enriched precision TIL strategy. This morning, we issued a press release, and the slides for today's webcast are available in the investor section of our corporate website at ir.iovance.com. Speaking on today's call is Dr. Fred Vogt, Interim CEO and President. During the question and answer session, we will also be joined by Dr. Noah Berkowitz, Dr. Brian Gastman, Dr. Raj Puri, Corleen Roche, and Dan Kirby.
This call will be including forward-looking statements regarding Iovance's goals, business focus, business plans, clinical trials and results, subgroup and biomarker analyses, trial enrollment and initiation, regulatory approvals, submissions, feedback and guidance, timelines, plans and strategies, potential future applications of our technologies, any required companion diagnostics, the size of addressable patient populations, and future updates. Forward-looking statements are subject to numerous risks and uncertainties, many of which are beyond our control, including the risks and uncertainties described from time to time in our SEC filings. Our results may differ materially from those projected during today's call. We undertake no obligation to publicly update any forward-looking statements. I will now turn the call over to Dr. Fred Vogt.
FULL TRANSCRIPT
Continue the full translated transcript in StockNow.
Access every statement, the English original, and speaker-by-speaker history with StockNow Pro.
View the full transcript with ProCall participants
8 people spoke on this call — only 2 are shown here.
PARTICIPANT LIST
View participant details in StockNow.
Log in to see executives and analysts, their roles, and complete speaking history.
Log in to view all participantsKeep exploring